Cancure Limited (“Cancure”) is a cancer drug development company established in 2012 on the Gold Coast, Queensland, Australia to consolidate and capitalise on over a decade of immuno-oncology research and development. Cancure aims to maximise patient response rates and hasten the evolution of cancer treatments into cancer cures.
Cancure’s three development programs – Genvax, Galectin, and Mitocans – are focused on the treatment and cure of cancer. Building on over a decade of leading research in each program, Cancure aims to advance three drug candidates to Phase 1 (Ph1) and Phase 2 (Ph2) clinical trials within 18 to 24 months.
Cancure has combined its founders’ scientific vision and passion with a commitment to meeting the commercial interest of committed investors. This has enabled the company to achieve the optimal blend of management, technology, and intellectual property, fully supported by an expert team which formulates and executes strategic development plans.